We speculate that hyperactive kinases, such as FLT3-ITD in AML cells or BCR-ABL in chronic myeloid leukemia cells and a subset of ALL cells [52], activate MYC and POLD1, and that this attenuates the cytotoxic effects of HDAC10 inhibition. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.